董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy Block | -- | Director | 69 | 29.22万美元 | 9.96 | 2024-06-20 |
| Michael Purcell | 男 | Director | 67 | 未披露 | 0.07 | 2024-06-20 |
| Kaouthar Lbiati | 女 | Director | 45 | 未披露 | 8.60 | 2024-06-20 |
| John P. Brancaccio | 男 | Executive Chairman | 76 | 30.35万美元 | 10.15 | 2024-06-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Cavan | 男 | Interim Chief Executive Officer and Chief Financial Officer | 66 | 176.68万美元 | 7.91 | 2024-06-20 |
董事简历
中英对照 | 中文 | 英文- Timothy Block
-
Timothy Block，自2013年11月26日起担任公司董事。Block博士是德雷塞尔大学医学院微生物学和免疫学教授，也是德雷塞尔生物技术和病毒学研究所所长，也是乙肝基金会（HBF）及其Baruch S. Blumberg研究所（以前称为肝炎和病毒研究所）的联合创始人和主席。Block博士还是宾夕法尼亚州生物技术中心的总裁兼首席执行官。Block博士作为专业研究员已成为医学院院系成员超过28年，发表了180多篇论文，12项美国专利，自2006年以来，已领导或“共同领导”了超过5000万美元的研究经费。荣誉包括荣誉医学博士（保加利亚医学院）；中央雄鹿商会终身成就奖；被Daily Intelligencer评为地区100位世纪最杰出人物之一；获得美国国家癌症研究所早期检测研究网络的杰出服务认可；以及美国众议院表彰“杰出成就”的特别引文。Block博士经常向美国国会和州立法机构提供证词；曾任职于美国FDA和众多NIH专家组以及包括百时美施贵宝（Bristol Myers Squibb）恩替卡韦顾问委员会在内的商业委员会。2009年，Block博士被任命为美国科学促进会（AAAS）的当选院士。
Timothy Block,has served as a director of Company since November 26, 2013. Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research). Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than 28 years, publishing more than 180 papers, 12 U.S. patents, and since 2006, has led or "co-led" more than $50 million in research funding. Honors include an honorary Medical Doctorate (Bulgarian Academy of Medicine); the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce; named one of the regions 100 Most Outstanding People of the Century by the Daily Intelligencer; Distinguished Service Recognition from the National Cancer Institute's Early Detection Research Network; and a Special Citation from the U.S. House of Representatives in recognition of "outstanding achievements." Dr. Block has given frequent testimony to the U.S. Congress and State legislatures; has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In 2009, Dr. Block was named an elected Fellow of the American Association for the Advancement of Science (AAAS). - Timothy Block，自2013年11月26日起担任公司董事。Block博士是德雷塞尔大学医学院微生物学和免疫学教授，也是德雷塞尔生物技术和病毒学研究所所长，也是乙肝基金会（HBF）及其Baruch S. Blumberg研究所（以前称为肝炎和病毒研究所）的联合创始人和主席。Block博士还是宾夕法尼亚州生物技术中心的总裁兼首席执行官。Block博士作为专业研究员已成为医学院院系成员超过28年，发表了180多篇论文，12项美国专利，自2006年以来，已领导或“共同领导”了超过5000万美元的研究经费。荣誉包括荣誉医学博士（保加利亚医学院）；中央雄鹿商会终身成就奖；被Daily Intelligencer评为地区100位世纪最杰出人物之一；获得美国国家癌症研究所早期检测研究网络的杰出服务认可；以及美国众议院表彰“杰出成就”的特别引文。Block博士经常向美国国会和州立法机构提供证词；曾任职于美国FDA和众多NIH专家组以及包括百时美施贵宝（Bristol Myers Squibb）恩替卡韦顾问委员会在内的商业委员会。2009年，Block博士被任命为美国科学促进会（AAAS）的当选院士。
- Timothy Block,has served as a director of Company since November 26, 2013. Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research). Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than 28 years, publishing more than 180 papers, 12 U.S. patents, and since 2006, has led or "co-led" more than $50 million in research funding. Honors include an honorary Medical Doctorate (Bulgarian Academy of Medicine); the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce; named one of the regions 100 Most Outstanding People of the Century by the Daily Intelligencer; Distinguished Service Recognition from the National Cancer Institute's Early Detection Research Network; and a Special Citation from the U.S. House of Representatives in recognition of "outstanding achievements." Dr. Block has given frequent testimony to the U.S. Congress and State legislatures; has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In 2009, Dr. Block was named an elected Fellow of the American Association for the Advancement of Science (AAAS).
- Michael Purcell
-
Michael Purcell在合并完成后于2018年加入董事会，并于2020年9月24日被任命为公司首席独立董事。Purcell先生是一名注册会计师，并于2015年退休后成为独立业务顾问。Purcell先生在Deloitte&Touche LLP“；Deloitte”；工作了超过36年，在那里他担任审计合伙人和Deloitte’；的中等市场和成长型企业服务的费城办公室负责人。Purcell先生曾在许多公司和组织的董事会任职，目前担任上市公司Tabula Rasa 医疗保健，Inc.，CFG Community Bank，Hyperion Bank，McKean Defense Group和其他几个营利性和非营利性实体的董事和审计委员会成员。他是the American Institute of Certified Public Accountants的成员，也是the Pennsylvania Institute of Certified Public Accountants费城分会的前总裁。Purcell先生拥有利哈伊大学的学士学位和德雷塞尔大学的工商管理硕士学位。
Michael Purcell,has served as a director of International Money Express, Inc. since 2018 and was appointed lead independent director for the Company on September 24, 2020. Mr. Purcell is a certified public accountant and became an independent business consultant following retirement in 2015. Mr. Purcell spent more than 36 years with Deloitte & Touche LLP ("Deloitte"), where he was an audit partner and the Philadelphia office leader of Deloitte's middle-market and growth enterprise services. Mr. Purcell has served on the boards of directors of numerous companies and organizations, and currently serves as chairman of the board, director and chair of the audit committee of publicly traded Tabula Rasa Healthcare, Inc. (NASDAQ: TRHC). Mr. Purcell also serves as a director and a member of the audit committee for each of CFG Bank and Hyperion Bank and as a director of several other for-profit and non-profit entities. He is a member of the American Institute of Certified Public Accountants and a former President of the Philadelphia Chapter of the Pennsylvania Institute of Certified Public Accountants. Mr. Purcell holds a bachelor's degree from Lehigh University and a master's degree in business administration from Drexel University. - Michael Purcell在合并完成后于2018年加入董事会，并于2020年9月24日被任命为公司首席独立董事。Purcell先生是一名注册会计师，并于2015年退休后成为独立业务顾问。Purcell先生在Deloitte&Touche LLP“；Deloitte”；工作了超过36年，在那里他担任审计合伙人和Deloitte’；的中等市场和成长型企业服务的费城办公室负责人。Purcell先生曾在许多公司和组织的董事会任职，目前担任上市公司Tabula Rasa 医疗保健，Inc.，CFG Community Bank，Hyperion Bank，McKean Defense Group和其他几个营利性和非营利性实体的董事和审计委员会成员。他是the American Institute of Certified Public Accountants的成员，也是the Pennsylvania Institute of Certified Public Accountants费城分会的前总裁。Purcell先生拥有利哈伊大学的学士学位和德雷塞尔大学的工商管理硕士学位。
- Michael Purcell,has served as a director of International Money Express, Inc. since 2018 and was appointed lead independent director for the Company on September 24, 2020. Mr. Purcell is a certified public accountant and became an independent business consultant following retirement in 2015. Mr. Purcell spent more than 36 years with Deloitte & Touche LLP ("Deloitte"), where he was an audit partner and the Philadelphia office leader of Deloitte's middle-market and growth enterprise services. Mr. Purcell has served on the boards of directors of numerous companies and organizations, and currently serves as chairman of the board, director and chair of the audit committee of publicly traded Tabula Rasa Healthcare, Inc. (NASDAQ: TRHC). Mr. Purcell also serves as a director and a member of the audit committee for each of CFG Bank and Hyperion Bank and as a director of several other for-profit and non-profit entities. He is a member of the American Institute of Certified Public Accountants and a former President of the Philadelphia Chapter of the Pennsylvania Institute of Certified Public Accountants. Mr. Purcell holds a bachelor's degree from Lehigh University and a master's degree in business administration from Drexel University.
- Kaouthar Lbiati
-
Kaouthar Lbiati，自2022年6月起担任公司董事。Lbiati博士是一位经验丰富的商业领袖，专注于价值创造、价值拐点里程碑和投资组合增长。自2017年11月以来，Dr Lbiati一直在帮助Cytovia Therapeutics、Steba Biotech和Immune制药等早期和晚期免疫肿瘤生物技术公司，更好地定义他们的公司战略，优化技术平台，优先考虑他们的管道和投资组合，有效地向投资者和合作伙伴推销他们的价值主张，以确保资金和交易。在Cytovia Therapeutics；一家专门从事NK细胞疗法的生物制药公司内，Lbiati博士担任非执行和执行职务。她于2020年5月开始担任CEO顾问，此后（3）个月，产品战略副总裁至2021年7月，战略与企业发展副总裁至2022年11月。此前，Lbiati博士曾在安进、葛兰素史克和赛诺菲担任全球和区域领导职务长达十多年，在那里她支持几种创新癌症药物如– Blincyto的注册、上市和/或适应症延长和报销，杰夫塔纳和Votrient–在美国、欧盟和中东和北非地区，重点关注医疗事务；战略规划、卫生经济学和成果研究；以及跨多个国家的市场准入。Lbiati博士在摩洛哥穆罕默德五世大学拉巴特获得医学博士学位，在巴黎古斯塔夫·鲁西研究所获得肿瘤学研究金，在巴黎ESSEC商学院获得战略与管理专业执行硕士学位，在伦敦经济学院获得国际政策和卫生经济学理学硕士学位。2022年，她获得了哥伦比亚商学院公司治理和哈佛商学院金融专业的认证。
Kaouthar Lbiati,has served as a director of Company since June 2022. Dr. Lbiati is an experienced business leader focusing on value creation, value-inflection milestones and portfolio growth. Since November 2017, Dr Lbiati has been helping early and late stage immune-oncology biotech companies such as, Cytovia Therapeutics, Steba Biotech and Immune Pharmaceuticals, better define their corporate strategy, optimize technology platforms, prioritize their pipeline and portfolio, effectively pitching their value proposition to investors and partners in order to secure funding and deals. Within Cytovia Therapeutics ; a biopharmaceutical company specializing in NK cell therapies, Dr Lbiati held non-executive and executive roles. She started as Advisor to the CEO in May 2020 for (3) months then, Vice President Product Strategy until July 2021 and Vice President, Strategy & Corporate Development until November 2022. Previously, Dr. Lbiati served, for over a decade, in global and regional leadership roles at Amgen, Glaxo Smith Kline, and Sanofi, where she supported the registration, launch and/or indication extension and reimbursement of several innovative cancer drugs such as – Blincyto, Jevtana and Votrient – in the U.S., EU and MENA regions, with a focus on medical affairs; strategic planning, health economics and outcomes research; and market access across multiple countries. Dr. Lbiati received a Doctor of Medicine degree from Rabat, Morocco's Mohammed V University, a fellowship in oncology from the Gustave Roussy Institute in Paris, a Specialized Executive Master's degree in Strategy & Management from ESSEC Business School in Paris, and a Master of Science in International Policy and Health Economics from the London School of Economics. In 2022, she was certified from Columbia Business School in Corporate Governance and from Harvard Business School in finance. - Kaouthar Lbiati，自2022年6月起担任公司董事。Lbiati博士是一位经验丰富的商业领袖，专注于价值创造、价值拐点里程碑和投资组合增长。自2017年11月以来，Dr Lbiati一直在帮助Cytovia Therapeutics、Steba Biotech和Immune制药等早期和晚期免疫肿瘤生物技术公司，更好地定义他们的公司战略，优化技术平台，优先考虑他们的管道和投资组合，有效地向投资者和合作伙伴推销他们的价值主张，以确保资金和交易。在Cytovia Therapeutics；一家专门从事NK细胞疗法的生物制药公司内，Lbiati博士担任非执行和执行职务。她于2020年5月开始担任CEO顾问，此后（3）个月，产品战略副总裁至2021年7月，战略与企业发展副总裁至2022年11月。此前，Lbiati博士曾在安进、葛兰素史克和赛诺菲担任全球和区域领导职务长达十多年，在那里她支持几种创新癌症药物如– Blincyto的注册、上市和/或适应症延长和报销，杰夫塔纳和Votrient–在美国、欧盟和中东和北非地区，重点关注医疗事务；战略规划、卫生经济学和成果研究；以及跨多个国家的市场准入。Lbiati博士在摩洛哥穆罕默德五世大学拉巴特获得医学博士学位，在巴黎古斯塔夫·鲁西研究所获得肿瘤学研究金，在巴黎ESSEC商学院获得战略与管理专业执行硕士学位，在伦敦经济学院获得国际政策和卫生经济学理学硕士学位。2022年，她获得了哥伦比亚商学院公司治理和哈佛商学院金融专业的认证。
- Kaouthar Lbiati,has served as a director of Company since June 2022. Dr. Lbiati is an experienced business leader focusing on value creation, value-inflection milestones and portfolio growth. Since November 2017, Dr Lbiati has been helping early and late stage immune-oncology biotech companies such as, Cytovia Therapeutics, Steba Biotech and Immune Pharmaceuticals, better define their corporate strategy, optimize technology platforms, prioritize their pipeline and portfolio, effectively pitching their value proposition to investors and partners in order to secure funding and deals. Within Cytovia Therapeutics ; a biopharmaceutical company specializing in NK cell therapies, Dr Lbiati held non-executive and executive roles. She started as Advisor to the CEO in May 2020 for (3) months then, Vice President Product Strategy until July 2021 and Vice President, Strategy & Corporate Development until November 2022. Previously, Dr. Lbiati served, for over a decade, in global and regional leadership roles at Amgen, Glaxo Smith Kline, and Sanofi, where she supported the registration, launch and/or indication extension and reimbursement of several innovative cancer drugs such as – Blincyto, Jevtana and Votrient – in the U.S., EU and MENA regions, with a focus on medical affairs; strategic planning, health economics and outcomes research; and market access across multiple countries. Dr. Lbiati received a Doctor of Medicine degree from Rabat, Morocco's Mohammed V University, a fellowship in oncology from the Gustave Roussy Institute in Paris, a Specialized Executive Master's degree in Strategy & Management from ESSEC Business School in Paris, and a Master of Science in International Policy and Health Economics from the London School of Economics. In 2022, she was certified from Columbia Business School in Corporate Governance and from Harvard Business School in finance.
- John P. Brancaccio
-
John P. Brancaccio，已退休的注册会计师；2005年12月起，担任本公司董事。他从2004年4月起，担任Accelerated Technologies的首席财务官，这是医疗器械公司的孵化器。他目前是Tamir Biotechnology（原Alfacell Corporation）、Synergy Pharmaceuticals、ContraVir Pharmaceuticals（Synergy的子公司）的董事。
John P. Brancaccio,a retired CPA, has served as Executive Chairman since March 2024 and a director of Company since May 15, 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004 until May 2020. He is also a director of Rasna Therapeutics, Inc. since September 2016, OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. - John P. Brancaccio，已退休的注册会计师；2005年12月起，担任本公司董事。他从2004年4月起，担任Accelerated Technologies的首席财务官，这是医疗器械公司的孵化器。他目前是Tamir Biotechnology（原Alfacell Corporation）、Synergy Pharmaceuticals、ContraVir Pharmaceuticals（Synergy的子公司）的董事。
- John P. Brancaccio,a retired CPA, has served as Executive Chairman since March 2024 and a director of Company since May 15, 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004 until May 2020. He is also a director of Rasna Therapeutics, Inc. since September 2016, OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020.
高管简历
中英对照 | 中文 | 英文- John Cavan
John Cavan，2016年4月1日以来，他一直担任我们的首席财务官。从2016年1月到2016年4月，他曾担任临时首席财务官。加入ContraVir公司之前，他曾担任The Pine Hill Group的顾问（2012年2月至2016年3月），在那里他曾协助完成多个战略和金融交易，包括首次公开发行、业务组合和战略事务。任职the Pine Hill Group之前，他曾担任Stemline Therapeutics, Inc的首席会计官，以及Aegerion Pharmaceuticals, Inc的副总裁兼首席会计官，在那里他曾协助公司的首次公开发行，通过Aegerion取得了20亿美元的市值（2006年6月至2012年2月）。他也曾担任医疗健康行业的财务职务，任职于 AlgoRx Pharmaceuticals, Inc.、Alpharma。职业生涯早期，他曾担任多种财务和运营职务，任职于大型跨国上市公司，其中包括Sony、American Express、International Specialty Products（Ashland Company）、Nestlé U.S.A.。他目前任职于Vantage Health Systems的董事会。
John Cavan,has been interim Chief Executive Officer since December 2023 and Chief Financial Officer since March 2016. Previously, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, includng Sony, American Express, International Specialty Products (an Ashland Company) and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University.- John Cavan，2016年4月1日以来，他一直担任我们的首席财务官。从2016年1月到2016年4月，他曾担任临时首席财务官。加入ContraVir公司之前，他曾担任The Pine Hill Group的顾问（2012年2月至2016年3月），在那里他曾协助完成多个战略和金融交易，包括首次公开发行、业务组合和战略事务。任职the Pine Hill Group之前，他曾担任Stemline Therapeutics, Inc的首席会计官，以及Aegerion Pharmaceuticals, Inc的副总裁兼首席会计官，在那里他曾协助公司的首次公开发行，通过Aegerion取得了20亿美元的市值（2006年6月至2012年2月）。他也曾担任医疗健康行业的财务职务，任职于 AlgoRx Pharmaceuticals, Inc.、Alpharma。职业生涯早期，他曾担任多种财务和运营职务，任职于大型跨国上市公司，其中包括Sony、American Express、International Specialty Products（Ashland Company）、Nestlé U.S.A.。他目前任职于Vantage Health Systems的董事会。
- John Cavan,has been interim Chief Executive Officer since December 2023 and Chief Financial Officer since March 2016. Previously, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, includng Sony, American Express, International Specialty Products (an Ashland Company) and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University.